ロード中...
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML
The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore per...
保存先:
| 主要な著者: | , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4108244/ https://ncbi.nlm.nih.gov/pubmed/24723466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23735 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|